Chronic lymphocytic leukaemia
Not recruitingStudy Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations
Study Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations
- Disease:Chronic lymphocytic leukaemia
- Substances:ObinutuzumabRituximab+4
France- Participants:18–64 years · 65+ years
- Substances:Obinutuzumab
- Sponsor:F. Hoffmann-La Roche AG









